Status:
COMPLETED
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to provide efficacy and safety data for monthly ranibizumab 0.5 mg intravitreal injections in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary t...
Eligibility Criteria
Inclusion
- Male or female Chinese patients 50 years of age or greater.
- Patients with primary or recurrent subfoveal CNV secondary to AMD.
- Patients who have a BCVA score from 73 to 24 characters in the study eye.
Exclusion
- Active, or history of, ocular inflammation or infection in the study eye within the last 30 days.
- Uncontrolled glaucoma in the study eye.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT00826371
Start Date
January 1 2009
Last Update
November 18 2016
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Beijing, China, 100044
2
Novartis Investigative Site
Beijing, China, 100730
3
Novartis Investigational Site
Chengdu, China, 610041
4
Novartis Investigative Site
Guangzhou, China, 510060